Cost-effectiveness of Pap smear screening for vaginal cancer after total hysterectomy for benign disease

Journal of Lower Genital Tract Disease

Volumn 7, Issue 3, 2003, Pages 194-202

  Fetters, Michael D ^a   Lieberman, Richard W ^b   Abrahamse, Paul H ^b   Sanghvi, Rupal V ^c   Sonnad, Seema S ^d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c Western Hemisphere Region ^*  (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer; Cost benefit analysis; Economics; Hysterectomy; Vaginal smears

Indexed keywords

FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; EVISCERATION; FEMALE; HUMAN; LASER SURGERY; LIFE EXPECTANCY; PAPANICOLAOU TEST; SENSITIVITY ANALYSIS; STATISTICAL MODEL; VAGINA CANCER; VAGINA SMEAR; VAGINAL HYSTERECTOMY;

EID: 0042623591     PISSN: 10892591     EISSN: None     Source Type: Journal    
DOI: 10.1097/00128360-200307000-00007     Document Type: Article

References (36)

1. Pokras R, Hufnagel VG. Hysterectomy in the United States, 1965-84. Am J Public Health 1988;78:852-3.
2. Graves EJ, Kozak LJ. National Center for Health Statistics. National hospital discharge survey: Annual summary, 1996. In: Vital and Health Statistics 13(139). Washington, DC: Government Printing Office; 1998:27.
3. Lee N, Dicker R, Rubin G, Ory H. Confirmation of the preoperative diagnoses for hysterectomy. Am J Obstet Gynecol 1984;150:283-7.
4. Carlson KJ, Nichols DH, Schiff I. Indications for hysterectomy. N Engl J Med 1993;328:856-60.
5. Eaker ED, Vierkant RA, Konitzer KA, Remington PL. Cervical cancer screening among women with and without hysterectomies. Obstet Gynecol 1998;91:551-5.
6. Miller J, Chambers D. The need for Pap tests after hysterectomy for benign disease: Results of a study of black patients. Postgrad Med J 1987;82:200-2205.
7. Piscitelli JT, Bastian LA, Simel DL. Cytologic screening after hysterectomy for benign disease. Am J Obstet Gynecol 1995;173:424-32.
8. Pearce KF, Haefner HK, Sarwar SF, Nolan TE. Cytopathological findings on vaginal Pap smears after cysterectomy for benign gynecologic disease. N Engl J Med 1996;335:1559-62.
9. Videlefsky A, Grossl N, Denniston M, Sehgal R, Lane JM, Goodenough G. Routine vaginal cuff smear testing in post-hysterectomy patients with benign uterine conditions: When is it indicated? J Am Board Fam Pract 2000;13:233-8.
10. Fetters MD, Fischer G, Reed BD. Effectiveness of vaginal Pap smear screening after total hysterectomy for benign disease. JAMA 1996;275:940-7.
11. Stevermer JJ, Wung L. Is there any benefit to Papanicolaou (Pap) test screening in women who have had a hysterectomy for benign disease? J Fam Pract 2001;50:111-2.
12. Saraiya M, Lee NC, Blackman D, Smith MJ, Morrow B, McKenna MT. Observations from the CDC. An assessment of Pap smears and hysterectomies among women in the United States. J Womens Health Gender-Based Med 2002;11:103-9.
13. Noller KL. Screening for vaginal cancer. N Engl J Med 1996;335:1599-600.
14. Weinstein MC, Fineberg HV, Elstein AS, et al. Clinical Decision Analysis. Philadelphia: W.B. Saunders; 1980:351.
15. Hagen MD. Decision analysis: A review. Fam Med 1992;24:349-54.
16. Beck JR, Paukers SG. The Markov process in medical prognosis. Med Decis Making 1983;3:419-58.
17. U.S. Preventive Services Task Force. Screening for cervical cancer. In: Task Force. Guide to Clinical Preventive Services. Baltimore: Williams & Wilkins, 1996;105-17.
18. Soost H, Lange H, Lehmacher W, Ruffing-Kullmann B. The validation of cervical cytology: Sensitivity, specificity, and predictive values. Acta Cytol 1991;35:8-14.
19. Boyes D, Morrison B, Knox E, Draper G, Miller A. A cohort study of cervical cancer screening in British Columbia. Clin Invest Med 1982;5:1-29.
20. Oxman AD, Guyatt GH. Guidelines for reading literature reviews. Can Med Assoc J 1988;138:697-702.
21. Cramer DW, Cutler SJ. Incidence and histopathology of malignancies of the female genital organs in the United States. Am J Obstet Gynecol 1970;118:443-60.
22. Herbst A, Green TJ, Ulfelder H. Primary carcinoma of the vagina. Am J Obstet Gynecol 1970;106:210-8.
23. Sox HCJ, Blatt MA, Higgins MC, Marton KI. Cost-effectiveness analysis and cost-benefit analysis. In: Medical Decision Making. Stoneham, MA: Butterworth-Heinemann 1988:317-35.
24. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weisert WG. Willingness to pay for a quality-adjusted life year: In search of a standard. Med Decis Making 2000;20:332-42.
25. Deyo RA. Cost-effectiveness of primary care. J Am Board Fam Pract 2000;13:47-54.
26. American Cancer Society Inc., 2001. Available at: http://www.cancer.org. Accessed February 24, 2003.
27. National Institutes of Health Consensus Development Conference State ment on Cervical Cancer. Consensus statement. Gynecol Oncol 1997;66:351-61.
28. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. Baltimore: Williams & Wilkins; 1996:1-504. Available at: http://www.ahcpr.gov/clinic/uspstfix.htm.
29. Grover SR, Quinn MA. Is there any value in bimanual pelvic examination as a screening test? Med J Aust 1995;162:408-10.
30. MacDonald ND, Rosenthal AN, Jacobs IJ. Screening for ovarian cancer. Ann Acad Med Singapore 1998;27:676-82.
31. Adonakis GL, Paraskevaidis E, Tsiga S, Seferiadis K, Lolis DE. A combined approach for the early detection of ovarian cancer in asymptomatic women. Eur J Obstet Gynecol Reprod Biol 1996;65:221-5.
32. U.S. Preventive Services Task Force. Screening for ovarian cancer. In: Fisher M, ed. Guide to Clinical Preventive Services. Baltimore: Williams & Wilkins 1989:159-66. Available at: http://www.ahcpr.gov/clinic/uspstf/uspsovar.htm
33. U.S. Preventive Services Task Force. Screening for cervical cancer. AHRQ Publication No. 03-515A, January 2003. Agency for Healthcare Research and Quality, Rockville, MD. Available at: http://www.ahrq.gov/clinic/3rduspstf/cervcan/cervcanwh.htm
34. Gold MR, Siegel JE, Russel LB, Weinstein MC, eds. Cost Effectiveness in Health and Medicine. New York: Oxford University Press; 1996:1-425.
35. Issued by National Center for Health Statistics. Hoyert DL, Arias E, Smith BL, et al. Deaths: Final Data for 1999. National Vital Statistics Report. Vol. 49, No. 8. Hyattsville, MD: National Center for Health Statistics, 2001.
36. Pride GL, Schultz AE, Chuprevich TW, Buchler DA. Primary invasive squamous carcinoma of the vagina. Obstet Gynecol 1979;53:218-25.